论文部分内容阅读
目的探讨哌罗匹隆对精神分裂症的疗效和安全性.方法90例精神分裂症患者随机分为两组,分别给予哌罗匹隆与奥氮平治疗8周,用阳性和阴性症状量表(PANSS)、副反应量表(TESS)评定疗效和副反应.结果哌罗匹隆组有效率为91.2%,奥氮平组有效率为96.5%,两组疗效差异无显著性(p>0.05);两组治疗中的不良反应发生率轻低、程度轻.结论哌罗匹隆与奥氮平治疗精神分裂症疗效相当,不良反应轻.两种药物均为疗效好、安全性高的抗精神病药.“,”Objective To explore the clinical efficacy and side effects of Perospirone and olanzapine in the treatment of schizophrenia. Methords 90 schizophrenia patients were randomly divided into Perospirone and olanzapine group for 8 weeks. PANSS and TESS were used to evaluate the clinical efficacy and side effects.Results There Were no significant difference in efficacy between two groups. (The effective rate of Perospirone group is 91.2%, The effective rate of olanzapine group is 96.5%). The incidence rate of side effects in both groups was low and the severity was mild..Conclusion Perospirone and olanzapine have equivalent efficacy and safety in the treatment of schizophrenia .